SLC5A2 and hydrops fetalis: Our study aims to explore the potential for SGLT2 inhibition to improve exercise tolerance and therefore the quality of life in patients with HF to an extent that may demonstrate significant improvements in standardized cardiopulmonary testing and potentially delay need for transplant or LVAD.